Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021085 · ClinicalTrials.gov registry record
Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies
A clinical trial of Fetal Sex Determination, sponsored by Sequenom.
- Completed
- Registry status
- 500
- Enrollment target
- 3
- Study locations
NCT01021085 is a study of Fetal Sex Determination that has completed, run by Sequenom. The registered enrollment target is 500 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01021085, a study of Fetal Sex Determination, has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
Whole blood and urine samples will be collected from pregnant woman of gestational age 36-56 days as confirmed by artificial reproductive technology (ART). The samples will be used to develop a prenatal sex test using circulating cell free fetal DNA (ccffDNA) in maternal plasma or urine.
Conditions Studied
Study Locations (3)
California
- San Diego Fertility Center - San Diego
Illinois
- Fertility Centers of Illinois - Glenview
Nevada
- Fertility Center of Las Vegas - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021085
The ClinicalTrials.gov registry entry for NCT01021085 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fetal Sex Determination appearing as the primary indexed condition, and to 0 interventions.
NCT01021085 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Nevada.
Frequently Asked Questions
What is clinical trial NCT01021085 about?
NCT01021085 is a clinical study titled "Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies". Whole blood and urine samples will be collected from pregnant woman of gestational age 36-56 days as confirmed by artificial reproductive technology (ART). The samples will be used to develop a prenatal sex test using circulating cell free fetal DNA (ccffDNA) in maternal plasma or urine.
What is the current status of trial NCT01021085?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2009-04. Estimated completion is 2011-09.
What conditions does trial NCT01021085 study?
This clinical trial studies the following conditions: Fetal Sex Determination.
Who is sponsoring clinical trial NCT01021085?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01021085 being conducted?
This trial has 3 study locations across California, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fetal Sex Determination
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.